What tesamorelin dosage did the clinical trials use?

The pivotal phase 3 trials used 2 mg of the original tesamorelin formulation by subcutaneous injection once daily for 26 weeks. That number belongs to an older formulation studied in adults with HIV-associated lipodystrophy. It should not be copied to a current brand or compounded vial, because formulation, concentration and approved indication differ.

Is tesamorelin taken daily or weekly?

Tesamorelin was given once daily in the registrational trials, and current Egrifta WR labeling also specifies once-daily administration. Its short plasma half-life and the daily evidence base do not support converting it to a weekly schedule. The prescriber determines the actual frequency for a compounded prescription.

How much tesamorelin is in the current Egrifta WR dose?

The March 2025 Egrifta WR label specifies 1.28 mg, or 0.16 mL of its reconstituted solution, once daily. FDA documentation says that amount produces exposure comparable to 2 mg of the original formulation. The formulations are not substitutable, so neither the milligram amount nor the volume should be transferred to a compounded vial.

Why is tesamorelin often scheduled in the evening?

Evening timing follows the physiology of the body's largest growth-hormone pulse, which commonly occurs soon after deep sleep begins. That is a clinical rationale, not proof that evening administration works better. Current Egrifta WR labeling requires once-daily use but does not name a clock time, so the prescriber sets timing for the individual prescription.

What does a prescriber monitor during tesamorelin treatment?

IGF-1 and glucose are the central laboratory signals. The current label recommends monitoring IGF-1 and considering discontinuation for persistent elevations, such as values above 3 SDS. Glucose is evaluated before and during therapy. Clinicians also watch for fluid retention, joint symptoms, carpal-tunnel symptoms and injection-site reactions.

Is compounded tesamorelin the same as Egrifta?

No. FDA-approved versions of tesamorelin exist, but the compounded formulation offered here is not FDA-approved. Its concentration and measured volume may differ from the brand. A licensed provider may prescribe a compounded formulation when medically appropriate, and the dispensing pharmacy's label—not a brand dose table—defines how that prescription is measured.

Tesamorelin Dosage: How Prescribers Set It

Tesamorelin dosage is daily rather than weekly in the registrational evidence and the current brand label. There is no single milligram number to copy, though: the pivotal trials studied 2 mg of an older formulation, the current Egrifta WR label specifies 1.28 mg, and a compounded prescription may have a different concentration. The pharmacy label controls the volume, while a prescriber uses the indication, IGF-1 response, glucose status and tolerability to decide whether the regimen remains appropriate.

That makes a tesamorelin dose a clinical decision, not a conversion exercise. The tesamorelin mechanism and evidence overview explains what the GHRH analogue does; this article stays with how dosing decisions are made.

What the tesamorelin dosage trials actually used

The pivotal evidence is unusually clear for a peptide. In a 26-week randomized trial of 412 adults with HIV and excess abdominal fat, investigators used 2 mg of the original tesamorelin formulation by subcutaneous injection every day. Visceral adipose tissue fell 15.2% in the tesamorelin group and rose 5.0% with placebo; IGF-1 rose 81.0% versus a 5.0% decline (Falutz et al., New England Journal of Medicine, 2007). Those numbers belong to that population, formulation and indication. They do not establish 2 mg as a general-purpose dose.

A pooled analysis of two phase 3 studies included 806 adults taking antiretroviral therapy. The same original 2 mg daily regimen produced a 15.4% placebo-adjusted reduction in visceral adipose tissue at 26 weeks, and the effect was maintained among participants who continued through week 52 (Falutz et al., Journal of Clinical Endocrinology & Metabolism, 2010). Again, this was HIV-associated abdominal fat accumulation, not ordinary weight management.

Evidence or formulation	Amount reported	Rhythm	What the number means
Pivotal phase 3 trials	2 mg	Once daily	Original 1 mg-per-vial formulation studied in adults with HIV-associated lipodystrophy
Current Egrifta WR label	1.28 mg (0.16 mL)	Once daily	11.6 mg-per-vial formulation with exposure comparable to the original 2 mg product
Compounded tesamorelin	Prescription-specific	Prescriber-set	Concentration and measured volume come from the pharmacy label, not the brand table

Why tesamorelin is daily, not weekly

Tesamorelin stimulates the pituitary to release the body's own growth hormone rather than supplying growth hormone directly. The current FDA label reports an elimination half-life of about 11 minutes for Egrifta WR, followed by the downstream GH and IGF-1 response. That short exposure and the daily schedules used in the controlled trials are why a weekly schedule cannot be inferred from the published evidence.

The formulation distinction matters just as much as frequency. The March 2025 Egrifta WR prescribing information says its 1.28 mg dose has similar systemic exposure to 2 mg of the original formulation and warns that Egrifta formulations are not substitutable. Equal milligram numbers do not necessarily mean equal exposure, and equal syringe volumes do not mean equal doses.

Why evening timing comes up

Growth hormone is naturally pulsatile. A classic sleep study found that the largest GH peak appeared with the onset of deep sleep and shifted when sleep onset shifted (Takahashi, Kipnis and Daughaday, Journal of Clinical Investigation, 1968). That physiology is why some prescribers place a daily tesamorelin injection in the evening: the timing tracks the normal overnight GH pulse.

But evening use is a rationale, not a requirement proven superior in the registrational trials. The current Egrifta WR label says once daily and does not specify morning or night. A separate 20-week trial in older adults used 1 mg 30 minutes before bedtime, but it studied cognition rather than HIV-associated lipodystrophy (Baker et al., Archives of Neurology, 2012). A consistent time that fits the prescription may matter more than claims about a perfect clock hour.

Weight and indication change what the number means

The approved brand dose is fixed for adults; it is not a milligram-per-kilogram formula. Body weight therefore does not justify multiplying a number from a dosing chart. A prescriber may still consider body composition, baseline metabolic markers and treatment response, but the registrational studies do not supply a validated weight-based calculator.

Indication is the larger boundary. Egrifta WR is labeled to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its label specifically says it is not indicated for weight-loss management and describes a weight-neutral effect. Using the phase 3 dose for a different goal assumes the same benefit-risk calculation without evidence that the populations are interchangeable.

Tesamorelin through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Distinct from the compounded formulation, the FDA-approved comparator is Egrifta WR, labeled to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision is between the patient and the doctor.

IGF-1 is the monitoring signal

IGF-1 is not a side detail. It is the downstream marker showing how strongly the GH axis is responding. The Egrifta WR label says to monitor IGF-1 during treatment and consider stopping when elevations remain above 3 standard-deviation scores. In the clinical program, 47% of treated participants were above 2 SDS and 36% were above 3 SDS at week 26.

That is why the dose on day one does not settle the question for month six. A prescriber looks at IGF-1 alongside swelling, joint discomfort, injection-site reactions and glucose. The label also calls for glucose evaluation before and during therapy; 5% of treated participants versus 1% on placebo crossed an HbA1c threshold of 6.5% by week 26. Persistently high IGF-1, worsening glucose or poor clinical response can change whether continuing makes sense.

What changes with a compounded vial

A compounded vial adds one more variable: concentration. Milligrams describe drug mass; milliliters describe liquid volume. The volume that represents a prescribed amount depends entirely on the concentration printed on that specific pharmacy label. A volume copied from Egrifta WR, an older vial or another pharmacy can deliver the wrong amount even when the syringe looks familiar.

The prescriber sets the actual dose, and the dispensing pharmacy translates it into the labeled volume for its formulation. How peptide reconstitution affects concentration explains the arithmetic without substituting for a prescription. When the vial, concentration or pharmacy changes, the old syringe volume should not be treated as a standing conversion.

What a prescriber decides before prescribing

A clinician weighs the proposed indication, baseline IGF-1 and glucose, pregnancy status, pituitary history, active or prior malignancy, current medicines and the ability to monitor over time. Fluid retention, carpal-tunnel symptoms and injection-site reactions can also change the benefit-risk judgment after treatment begins. The point is not to find the largest tolerated number. It is to find out whether ongoing GH-axis stimulation remains appropriate.

At Promise, a licensed provider reviews every request and decides whether tesamorelin is medically appropriate; not everyone qualifies. The visit and follow-up are the places to reconcile the prescribed milligrams with the vial concentration, timing and monitoring plan. What to expect from a first telehealth visit covers that review process.